SCORPIUS HOLDINGS INC (SCPX) Stock Price, Forecast & Analysis
USA - NYSEARCA:SCPX - US42237K5083 - Common Stock
SCPX Key Statistics, Chart & Performance
The current stock price of SCPX is 0.068 USD. In the past month the price decreased by -59.04%. In the past year, price decreased by -78.97%.
SCPX Latest News, Press Relases and Analysis
SCPX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.18 | 386.95B | ||
| AMGN | AMGEN INC | 14.43 | 169.90B | ||
| GILD | GILEAD SCIENCES INC | 15.07 | 153.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.98 | 106.72B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.37 | 68.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 863.71 | 57.74B | ||
| INSM | INSMED INC | N/A | 39.25B | ||
| NTRA | NATERA INC | N/A | 27.24B | ||
| BIIB | BIOGEN INC | 9.36 | 22.98B | ||
| INCY | INCYTE CORP | 16.39 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.2 | 20.53B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 37.03 | 15.35B |
Related stock screener links
About SCPX
Company Profile
Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company is headquartered in San Antonio, Texas and currently employs 82 full-time employees. The company went IPO on 2013-07-24. The firm couples Current Good Manufacturing Practices (CGMP) biomanufacturing and quality control knowledge with capabilities in immunoassays, molecular assays, and bioanalytical methods to support cell- and gene-based therapies as well as large molecule biologics using American-made equipment, reagents, and materials. The company offers an array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. The firm's CDMO service offerings also include enhanced microbial and mammalian development and manufacturing services.
Company Info
SCORPIUS HOLDINGS INC
1305 E. Houston Street, Building 2
San Antonio TEXAS US
Employees: 83
Phone: 19192407133
SCORPIUS HOLDINGS INC / SCPX FAQ
What does SCPX do?
Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company is headquartered in San Antonio, Texas and currently employs 82 full-time employees. The company went IPO on 2013-07-24. The firm couples Current Good Manufacturing Practices (CGMP) biomanufacturing and quality control knowledge with capabilities in immunoassays, molecular assays, and bioanalytical methods to support cell- and gene-based therapies as well as large molecule biologics using American-made equipment, reagents, and materials. The company offers an array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. The firm's CDMO service offerings also include enhanced microbial and mammalian development and manufacturing services.
What is the stock price of SCORPIUS HOLDINGS INC today?
The current stock price of SCPX is 0.068 USD. The price decreased by -48.48% in the last trading session.
Does SCPX stock pay dividends?
SCPX does not pay a dividend.
What is the ChartMill technical and fundamental rating of SCPX stock?
SCPX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in SCORPIUS HOLDINGS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SCPX.
Can you provide the short interest for SCPX stock?
The outstanding short interest for SCORPIUS HOLDINGS INC (SCPX) is 0.13% of its float.
SCPX Technical Analysis
SCPX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SCPX. Both the profitability and financial health of SCPX have multiple concerns.
SCPX Financial Highlights
Over the last trailing twelve months SCPX reported a non-GAAP Earnings per Share(EPS) of -1.38. The EPS increased by 20.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -72.96% | ||
| ROE | -128.83% | ||
| Debt/Equity | 0.31 |
SCPX Forecast & Estimates
7 analysts have analysed SCPX and the average price target is 5.1 USD. This implies a price increase of 7400% is expected in the next year compared to the current price of 0.068.
For the next year, analysts expect an EPS growth of 97.7% and a revenue growth 63.27% for SCPX